Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
Rhea-AI Summary
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) reported positive in vitro antimicrobial resistance (AMR) data for lead candidate Nu-3, a topical Bisphosphocin class compound for infected diabetic foot ulcers (iDFU). In 21-day serial‑passage studies, Nu-3 showed only slight MIC increase for E. coli and no MIC change for MRSA, while ciprofloxacin controls rose >2,000-fold (E. coli) and >600-fold (MRSA). Nu-3 retained activity against ciprofloxacin‑resistant isolates, supporting a low potential for resistance development and broad-spectrum activity against resistant pathogens.
Positive
- Nu-3 showed only a slight MIC increase for E. coli after 21 days of serial passage
- Nu-3 MIC remained unchanged for MRSA after 21 days of serial passage
- Nu-3 retained original MIC against ciprofloxacin‑resistant bacteria, indicating no cross‑resistance
Negative
- Data are in vitro only; clinical efficacy and safety in patients with iDFU are not yet demonstrated
- Results do not quantify clinical impact on amputation rates or healthcare costs for diabetic foot ulcers
News Market Reaction – LABT
In the May 1 session, LABT gained 28.95%, reflecting a significant positive market reaction. Argus tracked a peak move of +61.7% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Board appointment | Positive | +6.3% | Joseph Tucker added to board to support strategy and Bisphosphocin® program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The only recent event (a board appointment) saw a positive price reaction, contrasting with the pre-news weakness here.
In the past week, Lakewood-Amedex completed a Nasdaq direct listing and strengthened its board with Joseph Tucker, Ph.D., as disclosed in an April 28, 2026 announcement. That governance-focused news, tied to advancing the Bisphosphocin® program and Nu-3, was followed by a 6.28% gain. Today’s announcement adds scientific validation for Nu-3’s antimicrobial resistance profile, linking back to the same lead candidate and program highlighted in the prior governance news.
Key Terms
antimicrobial resistance medical
minimum inhibitory concentration (MIC) medical
methicillin-resistant staphylococcus aureus (MRSA) medical
vancomycin-resistant enterococci (VRE) medical
peripheral arterial disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins®
Nu-3 is one of a new class of antimicrobial compounds discovered by Lakewood-Amedex Biotherapeutics called the Bisphosphocin® class, which are also being explored in pre-clinical studies as potential treatments for complicated urinary tract infection (cUTI) and pulmonary infections. The Bisphosphocin® class of compounds have been shown in vitro to rapidly kill bacteria through a pH and concentration dependent destabilization of the bacterial cell membrane, typically achieving this effect in under one minute of exposure. This mechanism of action offers the potential to reduce the threat posed by antibiotic-resistant bacterial strains, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), and others.
In laboratory studies using a serial passage of E. coli and MRSA in the presence of Nu-3 for 21 days, Nu-3 showed slightly increased Minimum Inhibitory Concentration (MIC) at the end of the experiment for E. coli and were unchanged for MRSA. In contrast, the MIC for the ciprofloxacin control had increased over 2,000-fold for E. coli and over 600-fold for MRSA. In addition, Nu-3 maintained its original MIC when assessed against the bacteria that had developed resistance to Ciprofloxacin, which implies that cross-resistance did not occur.
"In experiments designed to induce resistance, the Bisphosphocin class has maintained its in vitro efficacy and potency, demonstrating a very low potential for resistance development, which confers enormous potential for our Nu-3 candidate targeting iDFU, and more broadly, as we work towards solutions for antimicrobial resistance, a major health challenge for our society," said Kelvin Cooper, Ph.D., Chief Executive Officer at Lakewood-Amedex Biotherapeutics. "Notably, the AMR data support our understanding of the mechanism of the Bisphosphocin® class of compounds, which we believe can provide a broad spectrum of activity against gram-positive, gram-negative, and multidrug-resistant organisms, and would provide a significant advantage over many existing antimicrobial classes."
The global AMR crisis is directly responsible for approximately 1.27 million deaths annually and contributes to nearly 5 million deaths worldwide. "Drug-resistant pathogens are a rising threat that have rendered many existing antibiotics ineffective, leading to increased mortality as well as higher healthcare costs and longer hospital stays," stated Thomas Balzer, MD, Ph.D., Chief Medical Officer and Senior Vice President, Clinical Development. "Of the approximately 830 million people who suffer from diabetes globally, about one third will develop a DFU in their life, of which about
About
About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Forward-Looking Statements
This press release may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words "believe," "expect," "intsend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause our Company's actual results to differ materially from historical experience and our present expectations or projections.
Relying on such statements involves risk, uncertainty and assumptions. These statements are based on the current estimates and assumptions of the management of Lakewood‐Amedex Biotherapeutics Inc. as of the date of this press release and are subject to uncertainty and changes. All statements obtained in this press release are made only as of the date of this press release and Lakewood‐Amedex Biotherapeutics Inc. does not undertake any obligation to publicly update any forward‐looking statements.
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-positive-antimicrobial-resistance-data-for-lead-candidate-targeting-infected-diabetic-foot-ulcers-302759775.html
SOURCE Lakewood-Amedex Biotherapeutics Inc.